Wegovy vs. Mounjaro.
Understanding the difference between GLP-1 and dual-action therapies. Backed by clinical data, delivered by Jace Medical.
Wegovy®
The established GLP-1.
Active Ingredient
Semaglutide
Mechanism Action
Single Receptor (GLP-1)
Clinical Trial Weight Loss*
Average ~15%
Administration
Weekly Injection
Device Type (UK)
FlexTouch Pen (4 doses)
Mounjaro®
The dual-action innovation.
Active Ingredient
Tirzepatide
Mechanism Action
Dual Receptor (GLP-1 + GIP)
Clinical Trial Weight Loss*
Average up to 21% (at highest dose)
Administration
Weekly Injection
Device Type (UK)
KwikPen (4 doses - Multi-use)
*Based on respective clinical trial data (STEP 1 & SURMOUNT-1) over 68-72 weeks. Individual results vary.
The Science: One Key vs. Two.
Both medications are effective, but they work in slightly different ways to regulate your appetite and metabolism.
Wegovy targets satiety.
Mimics the GLP-1 hormone to signal fullness to your brain and slow stomach emptying. It's like having a single key that locks away your hunger.
Mounjaro targets satiety & metabolism.
Mimics both GLP-1 AND GIP hormones. This dual action may improve how your body breaks down sugar and fat. It's like having two keys for double the control.
Simple, discreet administration.
Both medications use easy-to-use injection pens.
FlexTouch Pen
Attach disposable needle.
Dial to prescribed dose.
Press and hold for 10s.
What about side effects?
Common Questions
Can I switch from Wegovy to Mounjaro?
Which one works faster?
Is one more expensive?
Still unsure which is right for you?
Our clinical team will review your health profile and recommend the safest, most effective option.
Take the Eligibility Quiz